Literature DB >> 24857117

A value framework in head and neck cancer care.

Jonas A de Souza1, Tanguy Y Seiwert1.   

Abstract

The care of head and neck squamous cell carcinoma has greatly evolved over the past 30 years. From single modality to a multidisciplinary care, there has also been a concurrent increase in treatment intensity, resulting, at many times, in more zealous regimens that patients must endure. In this article, we apply Porter's value model as a framework to balance survival, toxicities, cost, and trade-offs from a patient's perspective in head and neck cancer. This model defines value as the health outcome per dollar achieved. Domains and outcomes that are important to patients, including not only survival or short-term quality of life, but also functional outcomes, recovery, sustainability of recovery, and the lasting consequences of therapy are included in this framework. Other outcomes that are seldom measured in head and neck cancer, such as work disability and financial toxicities, are also included and further discussed. Within this value model and based on evidence, we further discuss de-escalation of care, intensity-modulated radiation therapy, newer surgical methods, and enhancements in the process of care as potential approaches to add value for patients. Finally, we argue that knowing the patient's preferences is essential in the value discussion, as the attribute that will ultimately provide the most value to the individual patient with head and neck cancer.

Entities:  

Mesh:

Year:  2014        PMID: 24857117     DOI: 10.14694/EdBook_AM.2014.34.e304

Source DB:  PubMed          Journal:  Am Soc Clin Oncol Educ Book        ISSN: 1548-8748


  2 in total

1.  Evaluating Frameworks That Provide Value Measures for Health Care Interventions.

Authors:  Jeanne S Mandelblatt; Scott D Ramsey; Tracy A Lieu; Charles E Phelps
Journal:  Value Health       Date:  2017-02       Impact factor: 5.725

2.  Race and sex disparities in long-term survival of oral and oropharyngeal cancer in the United States.

Authors:  Nosayaba Osazuwa-Peters; Sean T Massa; Kara M Christopher; Ronald J Walker; Mark A Varvares
Journal:  J Cancer Res Clin Oncol       Date:  2015-10-28       Impact factor: 4.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.